CL2012002125A1 - Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito. - Google Patents

Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.

Info

Publication number
CL2012002125A1
CL2012002125A1 CL2012002125A CL2012002125A CL2012002125A1 CL 2012002125 A1 CL2012002125 A1 CL 2012002125A1 CL 2012002125 A CL2012002125 A CL 2012002125A CL 2012002125 A CL2012002125 A CL 2012002125A CL 2012002125 A1 CL2012002125 A1 CL 2012002125A1
Authority
CL
Chile
Prior art keywords
bioreactor
antibodies
purification
protein mixture
operational unit
Prior art date
Application number
CL2012002125A
Other languages
English (en)
Inventor
Diderick Reinder Kremer
Randal William Maarleleld
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of CL2012002125A1 publication Critical patent/CL2012002125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Método para la purificación de anticuerpos de una mezcla de proteína en un biorreactor; unidad operacional que se utiliza en el método antes descrito.
CL2012002125A 2010-02-12 2012-07-31 Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito. CL2012002125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10153529 2010-02-12

Publications (1)

Publication Number Publication Date
CL2012002125A1 true CL2012002125A1 (es) 2012-09-28

Family

ID=42133600

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002125A CL2012002125A1 (es) 2010-02-12 2012-07-31 Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.

Country Status (15)

Country Link
US (1) US20130131318A1 (es)
EP (1) EP2534169A1 (es)
JP (1) JP2013519652A (es)
KR (1) KR20120118065A (es)
CN (1) CN102762585B (es)
AR (1) AR080163A1 (es)
AU (1) AU2011214361C1 (es)
BR (1) BR112012020254A2 (es)
CA (1) CA2787897A1 (es)
CL (1) CL2012002125A1 (es)
EA (1) EA201201132A1 (es)
IL (1) IL221072A0 (es)
MX (1) MX2012009283A (es)
TW (1) TW201144327A (es)
WO (1) WO2011098526A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
ES2690213T3 (es) 2011-12-15 2018-11-19 Prestige Biopharma Pte. Ltd. Un método de purificación de anticuerpos
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CA2909969A1 (en) * 2013-05-13 2014-12-31 Medimmune, Llc Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN106103477B (zh) * 2014-03-04 2021-08-17 默克专利股份公司 稳健的抗体纯化
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
EP3233230B1 (en) * 2014-12-15 2024-06-12 Merck Patent GmbH Target molecule capture from crude solutions
CN105134271B (zh) * 2015-08-04 2017-06-16 山西晋城无烟煤矿业集团有限责任公司 综采工作面两端头过超高段液压支护装置
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
EA201990986A1 (ru) 2016-10-25 2019-09-30 Ридженерон Фармасьютикалз, Инк. Способы и системы анализа хроматографических данных
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
WO2019129878A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
CN111741770A (zh) 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
US12343702B2 (en) 2018-03-08 2025-07-01 Bio-Rad Laboratories, Inc. Anionic exchange-hydrophobic mixed mode chromatography resin
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
PT3894549T (pt) * 2018-12-10 2024-10-16 Amgen Inc Transposase piggybac mutada
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
GB201911686D0 (en) * 2019-08-15 2019-10-02 Fujifilm Diosynth Biotechnologies Uk Ltd Process for purifying target substances
EP4025336A4 (en) * 2019-09-05 2024-01-17 Bio-Rad Laboratories, Inc. ANION EXCHANGE/HYDROPHOBIC RESINS FOR MIXED MODE CHROMATOGRAPHY
EP4653865A3 (en) * 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US20230331773A1 (en) * 2022-04-15 2023-10-19 Pall Corporation Chromatography device and method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118912C1 (es) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
JP5025874B2 (ja) * 2000-03-27 2012-09-12 ジェネティクス インスティテュート，エルエルシー 高アニオン性タンパク質の精製方法
US20040002081A1 (en) * 2001-12-18 2004-01-01 Boehringer Ingelheim International Gmbh And Bia Separations D.O.O. Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale
US20060281087A1 (en) 2003-03-31 2006-12-14 Shuji Sonezaki Titanium dioxide complex having molecule distinguishability
WO2004087761A1 (ja) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
WO2006020622A1 (en) 2004-08-09 2006-02-23 Guild Associates, Inc. Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
WO2007075283A2 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
EP2253644B1 (en) * 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
WO2007073311A1 (en) * 2005-12-22 2007-06-28 Ge Healthcare Bio-Sciences Ab Preparation of biomolecules
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
US20100056759A1 (en) 2006-10-19 2010-03-04 Tolerx, Inc. Methods and Compositions for Efficient Removal of Protein A from Binding Molecule Preparations
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
AU2008206923A1 (en) * 2007-01-17 2008-07-24 Merck Serono S.A. Process for the purification of Fc-containing proteins
WO2009058769A1 (en) 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
US9527010B2 (en) * 2009-09-25 2016-12-27 Ge Healthcare Bio-Sciences Corp. Separation system and method

Also Published As

Publication number Publication date
CN102762585A (zh) 2012-10-31
TW201144327A (en) 2011-12-16
EA201201132A1 (ru) 2013-03-29
IL221072A0 (en) 2012-09-24
US20130131318A1 (en) 2013-05-23
CA2787897A1 (en) 2011-08-18
AU2011214361C1 (en) 2016-01-14
JP2013519652A (ja) 2013-05-30
MX2012009283A (es) 2012-09-07
AU2011214361A1 (en) 2012-08-23
EP2534169A1 (en) 2012-12-19
AU2011214361B2 (en) 2014-12-04
WO2011098526A1 (en) 2011-08-18
BR112012020254A2 (pt) 2016-05-03
KR20120118065A (ko) 2012-10-25
CN102762585B (zh) 2016-01-20
AR080163A1 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
CL2012002125A1 (es) Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
CO6531429A2 (es) Inhibidores de la tirosina quinasa de bruton
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
EA201300239A1 (ru) Антитела к fap и способы их применения
DK2637690T3 (da) Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
MX2019002979A (es) Formulaciones de anticuerpos.
DK2419429T3 (da) Imidazopyraziner som inhibitorer af proteinkinaser
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2016001166A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EP2367974A4 (en) MODIFICATION OF BIOMASS FOR EFFICIENT CONVERSION TO FUEL
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
EA201491224A1 (ru) Анти-псф-тау-антитела и их применение